| Identification | Back Directory | [Name]
Lorvotuzumab Mertansine | [CAS]
1008106-64-6 | [Synonyms]
Lorvotuzumab Mertansine
Research Grade Lorvotuzumab (DHC98501) |
| Hazard Information | Back Directory | [Uses]
Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity[1]. | [in vivo]
Lorvotuzumab mertansine (3-51 mg/kg, i.v., once) has potent anti-tumour activity in CB.17 SCID mice with SW2 SCLC xenograft tumor[1].
| Animal Model: | SW2 SCLC xenograft tumor CB.17 SCID mice | | Dosage: | 3、17 and 51 mg/kg | | Administration: | i.v., once | | Result: | Showed high anti-tumor activity at a dose of 17 mg/kg with half of the animals being tumor free and complete tumor regression at a dose of 51 mg/kg. |
| [References]
[1] Kathleen R Whiteman, et al. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66. DOI:10.4161/mabs.27756 |
|
| Company Name: |
Biolab Reagents
|
| Telephone: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
bioleaper
|
| Telephone: |
4000880777 17585207275 |
| Website: |
www.bioleaper.com/ |
|